R&D-Innovation > Projets de R&D labellisés > Biomarkers - In vitro & in vivo diagnostics

Biomarkers - In vitro & in vivo diagnostics

  • KeyMarker - Identification of new types of biomarkers and tracers for the in vivo molecular imaging of the pancreatic Beta-cell mass.

    The goal of KeyMarker is to identify molecules that can be used as radiotracers for PET or SPECT imaging and potential quantification of the pancreatic Beta-cell mass. Such molecules may lead to novel approaches for diabetic disease management, such as patient stratification, disease follow-up and therapeutic options. Several ligands for the target will be screened and evaluated through the preclinical models developed for the project. The in vitro/in vivo preclinical platform as well as the toxicology, bio-distribution and labeling expertise dedicated to the project form the ground for a standard process for further diabetes imaging tracer evaluation.

  • OncoMethylomic - New tools for the diagnosis of cancer and optimization of treatments against cancers.

    The goal of this project is to develop in vitro tests (I) of diagnosis of cancer and (II) of therapeutic personalization, based on the detection of methylation gene. This project mainly will make it possible to determine so some of these markers of methylation are able (I) to diagnose - and this in an early way - gynaecological cancers of the woman (in fact the breast cancer, endometer (or possibly ovary), and cervix), and (II) to provide indications making it possible to personalize a therapeutic vaccination among patients reached of lung cancers or melanomist, by classifying the responders and the non-responders with the treatment and by determining the profile of aggressiveness (forecast/risk of recurrence) of cancer. The project will combine the technology of MSP patented by WHO with simple and noninvasive techniques of sampling for these two types of tests. Moreover, tests starting from tissues samples will be also planned to predict the recurrence of these cancers.

  • Brainµ - Bacteria and Resistance to Antibiotics.  Identification using Nanotechnology and Microfluidics.

    The ultimate goal is to develop a test to identify within 1 h the main kinds of pathogenic bacteria and resistance parameters to antibiotics most commonly encountered in cases of bacteremia in order to allow doctors to quickly define the most adequate therapy, based on technical data rather than on empiricism. Blood cultures will be the samples of choice. The technology involves the extraction of DNA from pathogenic bacteria followed by multiplex hybridization on a microfluidic chip of extracted DNA.   Detection will be carried out with nanoparticles such as gold colloids, latex microspheres or fluorescent carbon nanotubes or fluorescent molecules. The purpose of the research is to develop a first generation of this platform to demonstrate the feasibility with a limited but clinically relevant targets. Research will therefore focus on three bacterial species and three resistance mechanisms of representative isolates that are frequent and of clinical and therapeutic importance in sepsis and recognized to be difficult to treat, i.e. Staphylococcus aureus and methicillin resistance (mecA), Escherichia coli and resistance induced by β-lactamases (extended spectrum CTX-M) and Pseudomonas aeruginosa with resistance to imipenem by metallo-β-lactamases [IMP and VIM]

  • Rheumagène - Development of a new diagnostic method of arthritis.

    The aim of this project is to validate the diagnostic value of transcriptomic and/or proteomic profiles of synovial material in early arthritis. It is based on preliminary data showing that gene expression profiles in synovial biopsies from patients with arthritis are able to discriminate the samples according to the underlying disorder. The large-scale confirmation of these data after this two-year project will lead to the development of a prototype of a diagnostic tool to be used in routine rheumatology practice.

  • VapChiP - Bacterial resistance assay in real time PCR on array for patients with Ventilator Associated Pneumonia (VAP).

    The aim of the project is a pre-validation of a new real time assay (VAP-technology) for the rapid detection of the bacterial species and their resistance in pneumonia. The assay was developed in order to provide microbiology laboratories with a rapid and multidata assay that would allow Intensive Care Unit (ICU) physicians to define a rationale for a first intention therapy tailored for individual patient. The project is a collaborative work between the industries and two universities laboratories for performing the validation studies.

  • Radiotarget - New 188Re-radiolabelled monoclonal antibodies in the fight against liver metastases.

    Early diagnosis of primary cancer, prior to any extension beyond the organ in which it was originally developed, usually allows treatment with surgical resection. However, significant proportions of patients with colorectal, breast or ovary cancers develop spread to the liver (liver metastases). Of these metastatic deposits, almost all are unresecable and cure is not possible. Eradication of such liver metastases might only be accomplished by systemic treatment which can reach cancer cells in all their implantation sites. In order to reduce adverse effects on healthy tissues, such treatment must however selectively target cell tumours. The aim of this project is to obtain a radioimmunotherapy agent, comprising the beta emitter 188Re and a monoclonal antibody able to selectively target and bind in vivo, on specific accessible biomarkers of metastatic liver. The availability of a high specific activity 188Re solution from a generator, with sufficient purity for labelling applications, has to be developed at GMP grade to support the clinical trials. Watch video